(CLCD) (CLCD) Stock Price, News & Analysis

Company Overview

CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company's lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.

Key Stats

• Today's Range: $46.53 to $46.53
• 50-Day Range: N/A
• 52-Week Range: $5.26 to $46.65
• Volume: N/A
• Average Volume: 708,479 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CLCD Stock Analysis - Frequently Asked Questions

How were (CLCD)'s earnings last quarter?

(CLCD) (NASDAQ:CLCD) released its quarterly earnings data on Wednesday, November, 9th. The biopharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.79).

When did (CLCD) IPO?

(CLCD) (CLCD) raised $55 million in an initial public offering on Wednesday, May 6th 2015. The company issued 5,500,000 shares at $10.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and William Blair was co-manager.

What other stocks do shareholders of (CLCD) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that (CLCD) investors own include Dova Pharmaceuticals (DOVA), Gilead Sciences (GILD), (KITE) (KITE), OPKO Health (OPK), Ariad Pharmaceuticals (ARIA), Biopharmx (BPMX) and Biostar Pharmaceuticals (BSPM).

Company Calendar

• Last Earnings: 11/09/2016
• Today: 6/22/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CLCD
• CIK: 1348649
• Web: www.colucid.com
• Phone: +1-781-3652596
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A